iRhythm Technologies, Inc. (IRTC)
Fair ValueFundamental
43
Price
$111.79
Market Cap
$3.75B
Part 1 · What the company is worth
Overview
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on September 18, 2026 with claude-haiku-4-5 — shared with all users
Its Preventice Solutions arm, acquired for $925 million, is the closest challenger to Zio in long-term continuous ECG patch monitoring in the United States.
Baxter owns Bardy Diagnostics, whose Carnation ambulatory monitor patch is prescribed for the same arrhythmia work-ups that Zio is used for.
GE HealthCare supplies the traditional 24-to-48-hour Holter monitors that hospitals and clinics can choose instead of sending a patient home with a Zio patch.
Through BioTelemetry, which it bought for $2.8 billion, Philips sells the wearable ECG patches and mobile cardiac telemetry services that compete directly with iRhythm's Zio for the same cardiologists and the same insurance reimbursement.
Medtronic's LINQ family of insertable cardiac monitors targets the same patients under investigation for atrial fibrillation and unexplained fainting, competing for the diagnostic referral before a Zio is ever prescribed.
This private US company sells the VitalPatch, a disposable ECG patch with AI arrhythmia detection sold to the same cardiology practices that buy Zio.
Balance Sheet & Liquidity
Revenue
$825M
Trailing 12 months (through 6/30/2026)
Net Income
$-14M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$35M
Total Equity
$153M
Total Liabilities
$867M
Current Ratio
3.85
Interest Coverage
1.89
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$104.37
Current Price
$111.79
Margin of Safety
-7.1%
Fair Value Range
$67.84 - $140.89
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-29.2%
P/B Ratio
20.14
P/FCF
96.12
Gross Margin
71.5%
ROIC
-2.2%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-2.2%
WACC
10.5%
ROIC − WACC
-12.7 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (12)
- EPS shows upward trend
- Price CAGR 14.06%
- Gross Margin 71.5%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 23.0%
- Analyst Consensus 95% Buy
- Earnings Surprise avg 3463.2%
- Net Margin Trend -1.7% vs -14.1%
- Piotroski F-Score 6/9
Failed (10)
- ROIC -2.2%
- P/FCF 96.12
- P/B Ratio 20.14
- Debt/Equity ratio
- Operating Margin -3.0%
- CapEx intensity
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -9.0%
- Share Dilution 2.7%
Unavailable (5)
- Dividend Payout NaN%
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Quentin S. Blackford | President, CEO & Director | 46 |
| Mr. Daniel G. Wilson | CFO & Principal Financial Officer | 43 |
| Dr. Minang P. Turakhia M.D., M.S. | Chief Medical & Scientific Officer and Executive VP of Advanced Technologies | 51 |
| Mr. Patrick Michael Murphy J.D. | Chief Business & Legal Officer | 46 |
| Mr. Chad M. Patterson | Chief Commercial and Product Officer | 43 |
| Mr. Mervin Smith | Executive Vice President of Business Operations | 50 |
| Mr. Marc Rosenbaum | Senior VP of Finance & Chief Accounting Officer | 52 |
| Mr. Brian Lawrence | Executive VP & CTO | 55 |
| Ms. Lisa Pecora | Senior Vice President of Finance & Investor Relations | - |
| Mr. Sean Clinton Freeman | Executive Vice President of Strategy & Corporate Development | 49 |
Audit Risk
9
Board Risk
5
Compensation Risk
3
Shareholder Rights Risk
7
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-19
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-06
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-22
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for IRTC, sourced from Markets Gazette.
- 3d agoPOSITIVEJP Morgan forecasts a 20x revenue increase for this AI stock
JP Morgan has significantly boosted its outlook for US-listed iRhythm Technologies Inc. (IRTC), forecasting a remarkable 20-fold increase in the company's revenue by 2030. This optimistic projection is underpinned by the escalating demand for computing power and a concurrent rise in the pricing power of 'neocloud' companies like iRhythm. In a September note, the bank upgraded IRTC from 'Underweight' to 'Overweight', signaling strong conviction in its future growth trajectory. Investors should monitor iRhythm's ability to capitalize on this burgeoning market, as the forecast suggests substantial upside potential.
- 6/16/2026NEGATIVEiRhythm Investigates Cyber Incident After Hackers Claim Access To Sensitive Data
iRhythm Technologies is investigating a cybersecurity incident where hackers claim to have accessed sensitive patient and proprietary data. The breach reportedly occurred via third-party applications. While the company states it does not foresee a material impact on its operations or finances, any data breach involving patient information can lead to regulatory scrutiny, reputational damage, and potential legal liabilities. Investors will monitor the situation closely for any further developments or undisclosed consequences that could affect the company's long-term prospects and stock valuation.
via Markets Gazette